Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Jachs

Showing results (11-20 of 118) with videos related to

Pageof 12
Sort By:
Hepatology (Baltimore, Md.)|June 9, 2025
Roadmap for a generally accepted model to predict first hepatic decompensation in compensated advanced chronic liver diseaseMattias Mandorfer, Mathias Jachs, Georg Semmler
Journal of Hepatology|February 6, 2022
Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfectionMathias Jachs, Bernhard Scheiner, Matthias Pinter
Hepatobiliary Surgery and Nutrition|December 12, 2025
Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertensionGeorg Semmler, Mathias Jachs, Mattias Mandorfer
Journal of Hepatology|March 23, 2023
Reply to: "3P and 5P models of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta"Mathias Jachs, Mattias Mandorfer, Thomas Reiberger
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 28, 2021
ReplyMathias Jachs, Thomas Reiberger, Mattias Mandorfer
Alimentary Pharmacology & Therapeutics|December 10, 2025
Editorial: ICG-R15 by PDD-A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease. Authors' ReplyMattias Mandorfer, Mathias Jachs, Tânia Carvalho, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2023
Editorial: Negative impact of diabetes mellitus and obesity on the prognosis of patients with chronic liver disease-Authors' replyRafael Paternostro, Mathias Jachs, Thomas Reiberger, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2023
Letter: NSBB for fatty liver disease-Still a long way to go. Authors' replyMathias Jachs, Rafael Paternostro, Thomas Reiberger, et al.
Wiener Klinische Wochenschrift|June 11, 2026
Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D : Case reportsMathias Jachs, Michael Schwarz, Mattias Mandorfer, et al.
Journal of Hepatology|March 20, 2022
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosisCaroline Schwarz, David Chromy, Christine Bangert, et al.
Pageof 12

Showing results (11-20 of 118) with videos related to

Sort By:
Pageof 12
Hepatology (Baltimore, Md.)|June 9, 2025
Roadmap for a generally accepted model to predict first hepatic decompensation in compensated advanced chronic liver diseaseMattias Mandorfer, Mathias Jachs, Georg Semmler
Journal of Hepatology|February 6, 2022
Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfectionMathias Jachs, Bernhard Scheiner, Matthias Pinter
Hepatobiliary Surgery and Nutrition|December 12, 2025
Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertensionGeorg Semmler, Mathias Jachs, Mattias Mandorfer
Journal of Hepatology|March 23, 2023
Reply to: "3P and 5P models of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta"Mathias Jachs, Mattias Mandorfer, Thomas Reiberger
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 28, 2021
ReplyMathias Jachs, Thomas Reiberger, Mattias Mandorfer
Alimentary Pharmacology & Therapeutics|December 10, 2025
Editorial: ICG-R15 by PDD-A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease. Authors' ReplyMattias Mandorfer, Mathias Jachs, Tânia Carvalho, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2023
Editorial: Negative impact of diabetes mellitus and obesity on the prognosis of patients with chronic liver disease-Authors' replyRafael Paternostro, Mathias Jachs, Thomas Reiberger, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2023
Letter: NSBB for fatty liver disease-Still a long way to go. Authors' replyMathias Jachs, Rafael Paternostro, Thomas Reiberger, et al.
Wiener Klinische Wochenschrift|June 11, 2026
Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D : Case reportsMathias Jachs, Michael Schwarz, Mattias Mandorfer, et al.
Journal of Hepatology|March 20, 2022
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosisCaroline Schwarz, David Chromy, Christine Bangert, et al.
Pageof 12